Genocea Provides Second Quarter 2020 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Genocea Biosciences (GNCA) Tops Q2 EPS by 1c
July 23, 2020 7:04 AM EDTGenocea Biosciences (NASDAQ: GNCA) reported Q2 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).
We continue to advance our clinical programs for patients living with cancer, said Chip Clark, President and Chief Executive Officer, Genocea. I am pleased by our ability to remain on... More
